PMA device
Avalus Bioprosthesis
Medtronic, Inc. · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision Jul 31, 2017, newest Jan 8, 2024Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
2
Naming "Avalus Bioprosthesis"
MAUDE reports
0
Brand "Avalus Bioprosthesis", since 2015
PubMed studies
10
Mentioning "Avalus Bioprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Avalus Bioprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 2 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Avalus Bioprosthesis", any status and sponsor, newest update first.
- Avalus Ultra Post-Approval Study (PAS)Active, not recruiting
Medtronic Cardiac SurgeryPublic (MDT)
NCT06506903 · 190 participants · Start Nov 20, 2024 · Primary completion Nov 2026
Device: Medtronic Avalus Ultra · For: Aortic Valve Disease
Sites: Hartford, Connecticut; Gainesville, Florida; Atlanta, Georgia · 15 sites in all
- Comparison of Two Pericardial Bioprostheses in AVRPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT03796442 · 140 participants · Start Jan 23, 2019 · Primary completion May 13, 2021
Device: AVR with AVALUS; AVR with CEPME · For: Aortic Valve Disease
Sites: Seongnam, South Korea; Seoul, South Korea
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Avalus Bioprosthesis", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LWR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Avalus Bioprosthesis"[tiab]. The summary above synthesizes these.
- Reply to Xiao et al.
Sabik JF, Rao V, Dagenais F, et al. · Eur J Cardiothorac Surg · 2025
- Minimally Invasive Aortic Valve Replacement in Contemporary Practice: Clinical and Hemodynamic Performance from a Prospective Multicenter Trial.
Velders BJJ, Vriesendorp MD, Reardon MJ, et al. · Thorac Cardiovasc Surg · 2023Multicenter Study
- Surgical Aortic Valve Replacement For Bicuspid And Tricuspid Valve Disease: 7-Year Outcomes In >1100 Patients.
Labrousse L, Moront MG, Dagenais F, et al. · Port J Card Thorac Vasc Surg · 2025
- Outcomes of Surgical Bioprosthetic Aortic Valve Replacement in Patients Aged ࣘ65 and >65 Years.
Kiaii BB, Moront MG, Patel HJ, et al. · Ann Thorac Surg · 2023Clinical Trial
- Two-Year Results of the 17-mm Avalus Aortic Valve in the PERIGON Japan Trial.
Okita Y, Fujita T, Zaikokuji K, et al. · Circ J · 2021Research Support, Non-U.S. Gov't
- Sizing Strategy and Implant Considerations for the Avalus Valve.
Moront MG, Sabik JF, Reardon MJ, et al. · Ann Thorac Surg · 2020
- Do postoperative hemodynamic parameters add prognostic value for mortality after surgical aortic valve replacement?
Velders BJJ, Vriesendorp MD, Asch FM, et al. · JTCVS Open · 2024
- Early and Midterm Outcomes of INSPIRIS RESILIA Versus AVALUS: A Propensity Score Matching Analysis.
Narita T, Nakayama T, Nishijima S, et al. · Heart Lung Circ · 2025Comparative Study
- Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis.
Sabik JF, Rao V, Dagenais F, et al. · Eur J Cardiothorac Surg · 2024Clinical Trial, Multicenter Study
- Management of TAVI Candidates With Metal Allergy: Minimally Invasive Aortic Valve Replacement With a Metal-Free Bioprosthesis.
Tanabe N, Tsuneyoshi H, Taki T, et al. · Ann Thorac Surg Short Rep · 2026Case Reports
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2026
- Mitroflow Aortic Pericardial Heart ValveCorcym Canada Corp · PMA 2019
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Ats 3F Aortic Bioprosthesis Model 1000Medtronic, Inc. · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.